zegerid with magnesium hydroxide- omeprazole, sodium bicarbonate and magnesium hydroxide tablet, chewable United States - English - NLM (National Library of Medicine)

zegerid with magnesium hydroxide- omeprazole, sodium bicarbonate and magnesium hydroxide tablet, chewable

santarus, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (sodium bicarbonate - unii:8mdf5v39qo), magnesium hydroxide (unii: nbz3qy004s) (magnesium hydroxide - unii:nbz3qy004s) - tablet, chewable - 20 mg - zegerid with magnesium hydroxide is indicated for short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. zegerid with magnesium hydroxide is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. (see clinical pharmacology, clinical studies, gastric ulcer.) zegerid with magnesium hydroxide is indicated for the treatment of heartburn and other symptoms associated with gerd. zegerid with magnesium hydroxide is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. (see clinical pharmacology, clinical studies.) the efficacy of zegerid with magnesium hydroxide used for longer than 8 weeks in these patients has not been established. in the rare instance of a patient not responding to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. if there is recurrence of erosive esophagitis or gerd symptoms (eg, hea

Capecitabine Sandoz capecitabine 150mg film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

capecitabine sandoz capecitabine 150mg film coated tablet blister pack

sandoz pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; croscarmellose sodium; titanium dioxide; purified talc; magnesium stearate; iron oxide red - colon cancer,capecitabine sandoz is indicated for the adjuvant treatment of patients with dukes' stage c and high-risk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer,capecitabine sandoz is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer,capecitabine sandoz is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer,capecitabine sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine sandoz in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

PREZCOBIX darunavir/cobicistat 800 mg/150 mg film coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

prezcobix darunavir/cobicistat 800 mg/150 mg film coated tablet bottle

janssen-cilag pty ltd - darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; silicon dioxide; magnesium stearate; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - prezcobix, a fixed dose combination of darunavir and cobicistat, is indicated in combination with other antiretroviral agents for the treatment of adult patients with human immunodeficiency virus- 1 (hiv-1) infection in:,- antiretroviral treatment-naive patients,- antiretroviral treatment-experienced patients with no darunavir resistance associated mutations and who have plasma hiv-1 rna <100,000 copies/ml,- antiretroviral treatment-experienced but hiv protease inhibitor-naive patients for whom hiv-1 genotype testing is unavailable (see section 4.2 dose and method of administration)

XELABINE capecitabine 150 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

xelabine capecitabine 150 mg film-coated tablet blister pack

viatris pty ltd - capecitabine, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; iron oxide yellow; microcrystalline cellulose; lactose; purified talc; titanium dioxide; iron oxide red; croscarmellose sodium; purified water - colon cancer:,capecitabine is indicated for the adjuvant treatment of patients with duke?s stage c and highrisk stage b, colon cancer, either as monotherapy or in combination with oxaliplatin.,colorectal cancer:,capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,oesophagogastric cancer:,capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,breast cancer:,capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

STADA IRBESARTAN HCT 150/12.5 irbesartan/hydrochlorothiazide 150 mg/12.5 mg tablet blister Australia - English - Department of Health (Therapeutic Goods Administration)

stada irbesartan hct 150/12.5 irbesartan/hydrochlorothiazide 150 mg/12.5 mg tablet blister

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; povidone; microcrystalline cellulose; magnesium stearate; hydrogenated castor oil; maize starch; lactose monohydrate - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Deptran 50 hexagonal tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

deptran 50 hexagonal tablet blister pack

alphapharm pty ltd - doxepin hydrochloride, quantity: 56.5 mg (equivalent: doxepin, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; lactose monohydrate; carnauba wax; purified talc; sodium starch glycollate; diethyl phthalate; magnesium stearate; titanium dioxide; indigo carmine; erythrosine; povidone - the 50mg and 75mg tablets are indicated only for the maintenance treatment of major depression. (see precautions).

CHEMISTS' OWN COUGH, COLD & FLU DAY/NIGHT tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

chemists' own cough, cold & flu day/night tablet blister pack

aspen pharma pty ltd - paracetamol, quantity: 500 mg; pseudoephedrine hydrochloride, quantity: 30 mg; chlorphenamine maleate, quantity: 2 mg - tablet, film coated - excipient ingredients: hydrogenated vegetable oil; croscarmellose sodium; pregelatinised maize starch; carnauba wax; magnesium stearate; microcrystalline cellulose; povidone; titanium dioxide; indigo carmine; hyprolose; iron oxide red; iron oxide black - provides fast and effective relief from the symptoms of cold and flu. the non-drowsy day tablet temporarily relieves: blocked noses, runny noses, nagging cough, headaches, body aches and pains, and fever. the night tablet contains an antihistamine and temporarily relieves: blocked noses, headaches, body aches and pains, and fever.

ABACAVIR/LAMIVUDINE 600/300 APOTEX abacavir 600mg (as sulfate) and lamivudine 300mg tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

abacavir/lamivudine 600/300 apotex abacavir 600mg (as sulfate) and lamivudine 300mg tablets bottle

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 8000; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

APO-Perindopril Arginine/Amlodipine 5/5 perindopril arginine 5 mg and amlodipine (as besilate) 5 mg uncoated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-perindopril arginine/amlodipine 5/5 perindopril arginine 5 mg and amlodipine (as besilate) 5 mg uncoated tablet bottle

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); perindopril arginine, quantity: 5 mg - tablet - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

APO-Perindopril Arginine/Amlodipine 5/10 perindopril arginine 5 mg and amlodipine (as besilate) 10 mg uncoated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-perindopril arginine/amlodipine 5/10 perindopril arginine 5 mg and amlodipine (as besilate) 10 mg uncoated tablet bottle

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); perindopril arginine, quantity: 5 mg - tablet - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.